Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jul;37(7):1468–1472. doi: 10.1128/aac.37.7.1468

Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers.

S C Flor 1, M C Rogge 1, A T Chow 1
PMCID: PMC187996  PMID: 8363378

Abstract

The bioequivalence of oral and intravenous ofloxacin was investigated after the administration of multiple doses of 400 mg every 12 h to 20 healthy male volunteers in a randomized, crossover, open-label study. Ofloxacin concentrations in plasma were evaluated after 4 days of oral or intravenous (1-h infusion) dosing with a 3-day wash-out period between regimens. As expected, delivery to the systemic circulation took slightly longer after the oral dosing (time to maximum concentration of drug in serum of 1.7 h) relative to the 1-h intravenous infusion, but the systemic availabilities of ofloxacin by the two routes of administration were equivalent (area under the concentration-time curve from 0 to 12 h ratio of 95%). Since previous studies have not demonstrated any change in the bioavailability of ofloxacin in infectious disease patients, this study supports the interchangeability of these dosing regimens.

Full text

PDF
1468

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auten G. M., Preheim L. C., Sookpranee M., Bittner M. J., Sookpranee T., Vibhagool A. High-pressure liquid chromatography and microbiological assay of serum ofloxacin levels in adults receiving intravenous and oral therapy for skin infections. Antimicrob Agents Chemother. 1991 Dec;35(12):2558–2561. doi: 10.1128/aac.35.12.2558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bitar N., Claes R., Van der Auwera P. Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally. Antimicrob Agents Chemother. 1989 Oct;33(10):1686–1690. doi: 10.1128/aac.33.10.1686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Guay D. R., Opsahl J. A., McMahon F. G., Vargas R., Matzke G. R., Flor S. Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1992 Feb;36(2):308–312. doi: 10.1128/aac.36.2.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Lode H., Höffken G., Olschewski P., Sievers B., Kirch A., Borner K., Koeppe P. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother. 1987 Sep;31(9):1338–1342. doi: 10.1128/aac.31.9.1338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Naber K. G., Adam D., Kees F. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. Drugs. 1987;34 (Suppl 1):44–50. doi: 10.2165/00003495-198700341-00011. [DOI] [PubMed] [Google Scholar]
  6. Pedersen S. S., Jensen T., Hvidberg E. F. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother. 1987 Oct;20(4):575–583. doi: 10.1093/jac/20.4.575. [DOI] [PubMed] [Google Scholar]
  7. Sanders W. E., Jr Oral ofloxacin: a critical review of the new drug application. Clin Infect Dis. 1992 Feb;14(2):539–554. doi: 10.1093/clinids/14.2.539. [DOI] [PubMed] [Google Scholar]
  8. Schuirmann D. J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657–680. doi: 10.1007/BF01068419. [DOI] [PubMed] [Google Scholar]
  9. Silvain C., Bouquet S., Breux J. P., Becq-Giraudon B., Beauchant M. Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis. Eur J Clin Pharmacol. 1989;37(3):261–265. doi: 10.1007/BF00679781. [DOI] [PubMed] [Google Scholar]
  10. Smith I. L., Schentag J. J. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci. 1984 Feb;73(2):281–282. doi: 10.1002/jps.2600730239. [DOI] [PubMed] [Google Scholar]
  11. Tartaglione T. A., Johnson C. R., Brust P., Opheim K., Hooton T. M., Stamm W. E. Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis. Antimicrob Agents Chemother. 1988 Nov;32(11):1640–1643. doi: 10.1128/aac.32.11.1640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Yew W. W., Lee J., Chan C. Y., Cheung S. W., Wong P. C., Kwan S. Y. Ofloxacin penetration into tuberculous pleural effusion. Antimicrob Agents Chemother. 1991 Oct;35(10):2159–2160. doi: 10.1128/aac.35.10.2159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Yuk J. H., Nightingale C. H., Quintiliani R., Sweeney K. R. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1991 Feb;35(2):384–386. doi: 10.1128/aac.35.2.384. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES